PRODUCTION OF AN ACELLULAR PERTUSSIS VACCINE (TOXOID)

NICHD正在继续评估NICHD无细胞百日咳 通过百日咳类毒素与白喉的组合， 破伤风类毒素，产生三价DTP疫苗。 所引用的 合同正在修改，以包括开发这种三价 在瑞典和美国的临床试验中进行有效性测试的产品。 AMVAX已提交了一份继续生产 百日咳类毒素及其与购买的白喉和百日咳的组合 破伤风类毒素 国家排雷中心的代表（包括主任， NICHD）审查了承包商在以下方面取得的进展： 大量百日咳类毒素的开发。 已确定AMVAX 应通过以下方式向NICHD提供0.7克混合散装百白破疫苗 1990年11月1日，将另外1.0 g散装百白破疫苗 1991年1月31日交付。

The NICHD is continuing its evaluation of the NICHD acellular pertussis toxoid through combination of the pertussis toxoid with diphtheria and tetanus toxoids, resulting in a trivalent, DTP, vaccine. The referenced contract is being modified to include the development of this trivalent product for efficacy testing in clinical trials in Sweden and the U.S. AMVAX has submitted a proposal for the continued production of the pertussis toxoid, and its combination with purchased diphtheria and tetanus toxoids. Representatives of the NICHD (including the Director, NICHD) have reviewed the progress that the contractor has made in the development of a bulk pertussis toxoid. It has been determined that AMVAX shall supply the NICHD with 0.7 grams of the combined bulk DTP vaccine by November 1, 1990, and an additional 1.0 gram of the bulk DTP vaccine to be delivered by January 31, 1991.